DHRDANAHER CORP /DE/

NYSE danaher.com


$ 273.17 $ 2.26 (0.83 %)    

Tuesday, 06-Aug-2024 13:36:54 EDT
QQQ $ 445.71 $ 7.91 (1.81 %)
DIA $ 392.63 $ 5.82 (1.5 %)
SPY $ 528.06 $ 8.54 (1.64 %)
TLT $ 96.84 $ -1.20 (-1.22 %)
GLD $ 221.05 $ -0.40 (-0.18 %)
$ 269.32
$ 270.90
$ 227.00 x 174
-- x --
$ 268.80 - $ 273.61
$ 181.51 - $ 281.70
2,632,644
na
199.94B
$ 0.87
$ 47.57
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-22-2024 06-28-2024 10-Q
2 04-22-2024 03-29-2024 10-Q
3 02-21-2024 12-31-2023 10-K
4 10-23-2023 09-29-2023 10-Q
5 07-24-2023 06-30-2023 10-Q
6 04-25-2023 03-31-2023 10-Q
7 02-22-2023 12-31-2022 10-K
8 10-19-2022 09-30-2022 10-Q
9 07-20-2022 07-01-2022 10-Q
10 04-20-2022 04-01-2022 10-Q
11 02-23-2022 12-31-2021 10-K
12 10-20-2021 10-01-2021 10-Q
13 07-21-2021 07-02-2021 10-Q
14 04-22-2021 04-02-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 10-22-2020 10-02-2020 10-Q
17 07-23-2020 07-03-2020 10-Q
18 05-06-2020 04-03-2020 10-Q
19 02-21-2020 12-31-2019 10-K
20 10-24-2019 09-27-2019 10-Q
21 07-18-2019 06-28-2019 10-Q
22 04-18-2019 03-29-2019 10-Q
23 02-21-2019 12-31-2018 10-K
24 10-18-2018 09-28-2018 10-Q
25 07-19-2018 06-29-2018 10-Q
26 04-19-2018 03-30-2018 10-Q
27 02-21-2018 12-31-2017 10-K
28 10-19-2017 09-29-2017 10-Q
29 07-20-2017 06-30-2017 10-Q
30 04-20-2017 03-31-2017 10-Q
31 02-22-2017 12-31-2016 10-K
32 10-20-2016 09-30-2016 10-Q
33 07-25-2016 07-01-2016 10-Q
34 04-21-2016 04-01-2016 10-Q
35 02-24-2016 12-31-2015 10-K
36 10-22-2015 10-02-2015 10-Q
37 07-23-2015 07-03-2015 10-Q
38 04-23-2015 04-03-2015 10-Q
39 02-25-2015 12-31-2014 10-K
40 10-16-2014 09-26-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jim-cramer-says-no-to-this-health-care-stock-recommends-holding-on-to-constellation-energy-its-up-a-huge-amount

Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot o...

 universal-health-services--lockheed-martin-were-among-top-11-large-cap-stocks-that-shined-the-brightest-last-week-july-21-july-27-are-the-others-in-your-portfolio

11 large-cap stocks saw significant gains in the last week, driven by positive earnings and guidance updates. Check if they'...

 freeport-mcmoran-pfizer-danaher-and-an-industrial-stock-cnbcs-final-trades

Freeport-McMoRan is Bryn Talkington's "final trade." On July 23, Freeport-McMoRan said second-quarter revenue came ...

 baird-maintains-outperform-on-danaher-raises-price-target-to-278

Baird analyst Catherine Schulte maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $271 to $278.

 rbc-capital-maintains-outperform-on-danaher-raises-price-target-to-300

RBC Capital analyst Conor McNamara maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $297 to $...

 barclays-maintains-equal-weight-on-danaher-raises-price-target-to-285

Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Equal-Weight and raises the price target from $270 to $285.

 leerink-partners-maintains-outperform-on-danaher-raises-price-target-to-280

Leerink Partners maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $275 to $280.

 stifel-maintains-hold-on-danaher-raises-price-target-to-250

Stifel analyst Daniel Arias maintains Danaher (NYSE:DHR) with a Hold and raises the price target from $235 to $250.

 goldman-sachs-maintains-neutral-on-danaher-raises-price-target-to-250

Goldman Sachs analyst Matthew Sykes maintains Danaher (NYSE:DHR) with a Neutral and raises the price target from $225 to $250.

 td-cowen-maintains-buy-on-danaher-raises-price-target-to-310

TD Cowen analyst Dan Brennan maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $290 to $310.

 b-of-a-securities-maintains-neutral-on-danaher-raises-price-target-to-275

B of A Securities analyst Derik De Bruin maintains Danaher (NYSE:DHR) with a Neutral and raises the price target from $270 t...

 life-science-giant-danahers-q2-earnings-beat-estimates-on-sustained-positive-momentum-in-bioprocessing-business-maintains-guidance

Danaher reported a 3% year-over-year decline in Q2 sales to $5.743 billion, surpassing the $5.59 billion consensus. Adjusted EP...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION